Patents Assigned to Anthrogenesis Corporation
-
Patent number: 9575054Abstract: Provided herein are methods of evaluating potential antitumor compounds, and thereby identifying antitumor compounds, using placenta or a portion thereof and tumor cells, and compositions for accomplishing the same. In one embodiment, provided herein is a method of determining whether a potential antitumor compound is effective against a plurality of tumor cells, comprising introducing a plurality of tumor cells to, e.g., into or onto, a mammalian placenta or portion thereof; contacting said plurality of tumor cells for a period of time with said antitumor compound; and determining whether said antitumor compound is effective against said tumor cells, wherein said antitumor compound is effective against said tumor cells if said antitumor compound over said period of time reduces the number of said tumor cells or reduces the growth rate of said tumor cells.Type: GrantFiled: February 22, 2013Date of Patent: February 21, 2017Assignee: Anthrogenesis CorporationInventors: Robert J. Hariri, Mohit B. Bhatia, Qian Ye
-
Publication number: 20170042944Abstract: Provided herein are compositions and methods for treating one or more disorders or conditions in infants, including premature infants, by administering to such infants umbilical cord blood or cells obtained from umbilical cord blood and, optionally, cells obtained from placental perfusate, placental stem cells and/or blood additives. Also provided herein are methods for treating one or more disorders or conditions in infants, including premature infants, by administering to such infants cells obtained from placental perfusate alone or placental stem cells alone or in combination with umbilical cord blood or cells obtained from umbilical cord blood.Type: ApplicationFiled: April 20, 2015Publication date: February 16, 2017Applicant: ANTHROGENESIS CORPORATIONInventors: Robert J. HARIRI, Jodi P. GURNEY, Xiaokui ZHANG, Stacy Herb, Cindy HARTUNG
-
Publication number: 20170007648Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.Type: ApplicationFiled: September 21, 2016Publication date: January 12, 2017Applicant: ANTHROGENESIS CORPORATIONInventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
-
Patent number: 9539288Abstract: The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.Type: GrantFiled: October 22, 2014Date of Patent: January 10, 2017Assignee: Anthrogenesis CorporationInventors: Casper Paludan, James W. Edinger, Ryhor Harbacheuski, RoseAnn Murray, Robert J. Hariri
-
Publication number: 20170002322Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: ApplicationFiled: September 12, 2016Publication date: January 5, 2017Applicant: Anthrogenesis CorporationInventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
-
Publication number: 20170000779Abstract: The present invention relates to methods of modulating mammalian stem cell and progenitor cell differentiation. The methods of the invention can be employed to regulate and control the differentiation and maturation of mammalian, particularly human stem cells along specific cell and tissue lineages. The methods of the invention relate to the use of certain small organic molecules to modulate the differentiation of stem or progenitor cell populations along specific cell and tissue lineages, and in particular, to the differentiation of embryonic-like stem cells originating from a postpartum placenta or for the differentiation of early progenitor cells to a granulocytic lineage. Finally, the invention relates to the use of such differentiated stem or progenitor cells in transplantation and other medical treatments.Type: ApplicationFiled: February 8, 2016Publication date: January 5, 2017Applicants: Anthrogenesis Corporation, Celgene Corporation, Signal PharmaceuticalsInventors: Robert J. Hariri, David Stirling, Laure A. Moutouh-De Parseval, Kyle W.H. Chan
-
Publication number: 20170000828Abstract: Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.Type: ApplicationFiled: September 22, 2016Publication date: January 5, 2017Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, Kathy E. Karasiewicz-Mendez, Vanessa Voskinarian-Berse, Xiaokui Zhang
-
Publication number: 20160362659Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perforate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrate erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: ApplicationFiled: December 22, 2015Publication date: December 15, 2016Applicant: Anthrogenesis CorporationInventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
-
Publication number: 20160361366Abstract: Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.Type: ApplicationFiled: October 22, 2015Publication date: December 15, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Aleksandr Kaplunovsky, Vladimir Jankovic, Kristen Labazzo, Eric Law, Neerav Padliya, Jennifer Paredes, Jia-Lun Wang
-
Publication number: 20160354408Abstract: Provided herein are micro-organoids, referred to herein as Functional Physiological Units (FPUs), that are capable of replacing or augmenting one or more physiological functions in an individual, which are useful in the treatment of individuals lacking, or suffering a deficit in, said physiological function.Type: ApplicationFiled: February 10, 2015Publication date: December 8, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Robert J. HARIRI, Mohit BHATIA, Jia-Lun WANG, Wolfgang HOFGARTNER, Qian YE
-
Publication number: 20160304832Abstract: Provided herein are methods of culturing cells using microcarriers that include extracellular matrix (ECM).Type: ApplicationFiled: June 23, 2014Publication date: October 20, 2016Applicant: Anthrogenesis CorporationInventors: Robert J. HARIRI, Mohit BHATIA
-
Publication number: 20160298084Abstract: The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.Type: ApplicationFiled: June 22, 2016Publication date: October 13, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Mohammad Heidaran, Jia-Lun Wang, Andrew Zeitlin, Colleen Suzanne Dulaney
-
Patent number: 9464274Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: GrantFiled: November 18, 2014Date of Patent: October 11, 2016Assignee: Anthrogenesis CorporationInventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Publication number: 20160287635Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.Type: ApplicationFiled: November 16, 2015Publication date: October 6, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Publication number: 20160289634Abstract: A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.Type: ApplicationFiled: June 9, 2016Publication date: October 6, 2016Applicant: Anthrogenesis CorporationInventor: Robert J. Hariri
-
Publication number: 20160279171Abstract: Provided herein are compositions comprising mononuclear cells from human placental perfusate and methods of using such cells, including using the cells together with hematopoietic cells, for example to establish chimerism, reduce the severity or duration of graft versus host disease, treat or ameliorate symptoms of sarcopenia, metabolic disorders and hematologic disorders, such as hematologic malignancies, and treat or ameliorate symptoms of ischemic encephalopathy (e.g., hypoxic ischemic encephalopathy) and other central nervous system injuries.Type: ApplicationFiled: November 14, 2014Publication date: September 29, 2016Applicant: Anthrogenesis CorporationInventors: Jodi P. Gurney, Xiaokui Zhang, Stacy Herb, Robert J. Hariri
-
Publication number: 20160235790Abstract: Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.Type: ApplicationFiled: October 2, 2014Publication date: August 18, 2016Applicant: Anthrogenesis CorporationInventors: Jodi P. GURNEY, Xiaokui ZHANG, Stacy HERB, Robert J. HARIRI
-
Publication number: 20160220618Abstract: An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.Type: ApplicationFiled: March 11, 2016Publication date: August 4, 2016Applicant: ANTHROGENESIS CORPORATIONInventor: Naoko TAKEBE
-
Patent number: 9387283Abstract: A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.Type: GrantFiled: June 6, 2014Date of Patent: July 12, 2016Assignee: Anthrogenesis CorporationInventor: Robert J. Hariri
-
Patent number: 9364585Abstract: An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.Type: GrantFiled: December 10, 2012Date of Patent: June 14, 2016Assignee: ANTHROGENESIS CORPORATIONInventor: Naoko Takabe